Cargando…

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Yoon Yang, Hyun, Chang Lim, Jin, Min-Sun, Park, In Ae, Chung, Yul Ri, Shim, Bobae, Lee, Kyu Ho, Ryu, Han Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053310/
https://www.ncbi.nlm.nih.gov/pubmed/27721875
http://dx.doi.org/10.4048/jbc.2016.19.3.261
_version_ 1782458389421359104
author Jung, Yoon Yang
Hyun, Chang Lim
Jin, Min-Sun
Park, In Ae
Chung, Yul Ri
Shim, Bobae
Lee, Kyu Ho
Ryu, Han Suk
author_facet Jung, Yoon Yang
Hyun, Chang Lim
Jin, Min-Sun
Park, In Ae
Chung, Yul Ri
Shim, Bobae
Lee, Kyu Ho
Ryu, Han Suk
author_sort Jung, Yoon Yang
collection PubMed
description PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHODS: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled. The core needle biopsy specimens acquired before NAC were used to analyze the clinicopathologic variables and overall performance of the predictive model for therapeutic response. RESULTS: Independent predictors of pathologic complete response after NAC were found to be higher number of tumor infiltrating lymphocytes (p=0.007), absence of clear cytoplasm (p=0.008), low necrosis (p=0.018), and high histologic grade (p=0.039). In the receiver operating characteristics curve analysis, the area under curve for the combination of these four variables was 0.777. CONCLUSION: The present study demonstrated that a predictive model using the above four variables can predict therapeutic response to single-regimen NAC with the combination of doxorubicin, cyclophosphamide, and docetaxel in TNBC. Therefore, adding these morphologic variables to clinical and genomic signatures might enhance the ability to predict the therapeutic response to NAC in TNBC.
format Online
Article
Text
id pubmed-5053310
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Breast Cancer Society
record_format MEDLINE/PubMed
spelling pubmed-50533102016-10-07 Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Jung, Yoon Yang Hyun, Chang Lim Jin, Min-Sun Park, In Ae Chung, Yul Ri Shim, Bobae Lee, Kyu Ho Ryu, Han Suk J Breast Cancer Original Article PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHODS: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled. The core needle biopsy specimens acquired before NAC were used to analyze the clinicopathologic variables and overall performance of the predictive model for therapeutic response. RESULTS: Independent predictors of pathologic complete response after NAC were found to be higher number of tumor infiltrating lymphocytes (p=0.007), absence of clear cytoplasm (p=0.008), low necrosis (p=0.018), and high histologic grade (p=0.039). In the receiver operating characteristics curve analysis, the area under curve for the combination of these four variables was 0.777. CONCLUSION: The present study demonstrated that a predictive model using the above four variables can predict therapeutic response to single-regimen NAC with the combination of doxorubicin, cyclophosphamide, and docetaxel in TNBC. Therefore, adding these morphologic variables to clinical and genomic signatures might enhance the ability to predict the therapeutic response to NAC in TNBC. Korean Breast Cancer Society 2016-09 2016-09-23 /pmc/articles/PMC5053310/ /pubmed/27721875 http://dx.doi.org/10.4048/jbc.2016.19.3.261 Text en © 2016 Korean Breast Cancer Society. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jung, Yoon Yang
Hyun, Chang Lim
Jin, Min-Sun
Park, In Ae
Chung, Yul Ri
Shim, Bobae
Lee, Kyu Ho
Ryu, Han Suk
Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_full Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_fullStr Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_full_unstemmed Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_short Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_sort histomorphological factors predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053310/
https://www.ncbi.nlm.nih.gov/pubmed/27721875
http://dx.doi.org/10.4048/jbc.2016.19.3.261
work_keys_str_mv AT jungyoonyang histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT hyunchanglim histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT jinminsun histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT parkinae histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT chungyulri histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT shimbobae histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT leekyuho histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT ryuhansuk histomorphologicalfactorspredictingtheresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer